SS-31 and MOTS-c: How These Mitochondrial Peptides Compare

SS-31 and MOTS-c are both research peptides linked to mitochondrial function, but they are not interchangeable. SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin on the inner mitochondrial membrane, while MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA that influences metabolic signaling through AMPK. Neither peptide is FDA-approved for human use in the United States.

What Is SS-31 (Elamipretide)?

SS-31 is a short, cell-permeable peptide designed to concentrate inside mitochondria. Its sequence — D-Arg-Dmt-Lys-Phe-NH2 — includes a dimethyltyrosine residue that provides antioxidant activity and a positive charge that helps it associate with cardiolipin, a phospholipid on the inner mitochondrial membrane.

Researchers study SS-31 because cardiolipin oxidation is tied to mitochondrial dysfunction, and stabilizing cardiolipin may help preserve electron transport chain efficiency. The compound has been tested in human trials for Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration, with mixed results.

• Class: Synthetic mitochondria-targeted tetrapeptide
• Also known as: Elamipretide, MTP-131, Bendavia
• Studied routes: Subcutaneous injection and intravenous infusion
• Regulatory status: Not FDA-approved; investigational in the U.S.

What Is MOTS-c?

MOTS-c is a mitochondrial-derived peptide encoded within the 12S ribosomal RNA region of mitochondrial DNA. Unlike SS-31, MOTS-c is produced naturally by the body, and research suggests it can travel from mitochondria to the nucleus, where it influences gene expression.

Published studies describe MOTS-c as a regulator of metabolic homeostasis. It activates AMPK, a central energy sensor, and has been examined in the context of insulin sensitivity, exercise response, and age-related metabolic decline. Most of the evidence comes from animal models and cell cultures rather than human trials.

• Class: Endogenous mitochondrial-derived peptide
• Size: 16 amino acids
• Primary pathway: AMPK activation and folate-methionine cycle signaling
• Human data: Limited; no approved therapeutic indication

SS-31 vs. MOTS-c: How They Compare

The two peptides share a mitochondrial theme but differ in origin, size, and mechanism. The table below summarizes the main distinctions researchers point to.

Feature	SS-31 (Elamipretide)	MOTS-c
Origin	Synthetic tetrapeptide	Endogenous mitochondrial-derived peptide
Length	4 amino acids	16 amino acids
Primary mechanism	Binds cardiolipin and reduces reactive oxygen species at the inner membrane	Activates AMPK and modulates metabolic gene expression
Studied areas	Barth syndrome, mitochondrial myopathy, heart failure, dry AMD	Metabolic regulation, insulin sensitivity, exercise response
Human trial data	Multiple phase 2 and phase 3 trials	Very limited
FDA status	Not approved	Not approved
Typical research quantity	10 mg and 30 mg vials	10 mg vials

Dosing in Research Settings

There is no established human dose for either peptide outside of clinical trials. In published SS-31 trials, intravenous infusions have ranged from roughly 0.05 to 0.25 mg/kg/hour, while subcutaneous doses of 40 mg daily have been used in studies of Barth syndrome and heart failure.

Peptide vendors typically sell SS-31 in 10 mg and 30 mg vials, and community discussions of ss-31 peptide dosing often describe 5–10 mg subcutaneously per day. Those numbers come from anecdotal reports, not controlled human data. Any discussion of ss-31 peptide injection dosage should be framed as strictly experimental.

MOTS-c is commonly described in research forums at 5–15 mg per day subcutaneously, but human pharmacokinetic data are essentially absent. Because neither peptide is approved, dosing decisions belong with a licensed healthcare professional.

Reported Side Effects and Safety

In clinical trials of elamipretide, the most frequently reported ss 31 side effects were injection-site reactions, headache, nausea, and dizziness. Some trials also noted transient blood pressure changes during infusion.

MOTS-c has far less human safety data. Because it is an endogenous peptide involved in metabolic signaling, researchers caution that long-term effects on glucose metabolism and cellular stress responses are not well understood.

Neither peptide is a proven treatment for any condition. Self-administered research peptides carry risks that include contamination, incorrect dosing, and unknown interactions with prescription medications, so anyone considering them should talk with a healthcare professional first.

Legal Status and Sourcing

SS-31 and MOTS-c are sold in the United States as research chemicals, not as approved drugs. They are therefore not subject to the same manufacturing, purity, and labeling standards as prescription medicines.

People searching for where to buy ss-31 peptide online will find dozens of vendors with widely varying certificates of analysis. A vial labeled 30 mg may contain a different amount, a different salt form, or degraded peptide. Independent laboratory testing is one way researchers screen suppliers.

Buying peptides for personal use occupies a legal gray area. The FDA has issued warning letters to companies marketing unapproved peptides, and importing them for personal use is not clearly legal.

Can You Use ss-31 and mots-c together?

There are no published clinical studies of ss-31 and mots-c together. Because their mechanisms differ — cardiolipin stabilization versus AMPK-mediated metabolic signaling — some researchers speculate they could be complementary, but that idea remains untested.

Stacking unapproved peptides increases the chance of unexpected interactions and makes it harder to attribute any side effect to a single compound. Anyone considering combining them should discuss it with a physician who understands the current evidence base.

The Bottom Line

SS-31 and MOTS-c are both mitochondrial research peptides, but they are distinct molecules with different origins, mechanisms, and evidence bases. SS-31 has reached phase 2 and phase 3 human trials with mixed outcomes, while MOTS-c remains largely preclinical.

Neither peptide is FDA-approved, dosing is not standardized, and safety data are incomplete. For now, the most reliable conclusions come from peer-reviewed trials, not vendor marketing or forum anecdotes.

COMMON QUESTIONS

Frequently Asked Questions

Is SS-31 the same as MOTS-c?

No. SS-31 is a synthetic four-amino-acid peptide that binds cardiolipin on the inner mitochondrial membrane, while MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA that works mainly through AMPK signaling. They are studied for different purposes and are not interchangeable.

Is SS-31 approved by the FDA?

No, SS-31 (elamipretide) is not FDA-approved for any human use in the United States. It has been tested in phase 2 and phase 3 clinical trials for conditions such as Barth syndrome and heart failure, but it remains investigational and recalls have been issued for unapproved versions.

How is MOTS-c dosed in research?

There is no established human dose for MOTS-c. Research forums commonly describe subcutaneous doses of 5–15 mg per day, but those figures come from anecdotal reports rather than controlled human trials. Anyone considering it should consult a licensed healthcare professional.